These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34082835)

  • 1. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan K; Romley JA; Myerson R
    BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
    Li Y; Xu S
    JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program.
    Owsley KM; Bradley CJ
    Health Aff (Millwood); 2023 Jun; 42(6):785-794. PubMed ID: 37276477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between initiation of 340B participation and hospital safety-net engagement.
    Nikpay SS; Buntin MB; Conti RM
    Health Serv Res; 2020 Apr; 55(2):157-169. PubMed ID: 32187392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. US Hospital Service Availability and New 340B Program Participation.
    Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
    JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 340B Drug Pricing Program and hospital provision of uncompensated care.
    Desai SM; McWilliams JM
    Am J Manag Care; 2021 Oct; 27(10):432-437. PubMed ID: 34668672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notice regarding section 602 of the Veterans Health Care Act of 1992 inclusion of outpatient hospital facilities--PHS. Notice.
    Fed Regist; 1994 Jun; 59(107):29300-1. PubMed ID: 10135125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.
    Levengood TW; Conti RM; Cahill S; Cole MB
    Milbank Q; 2024 Jun; 102(2):429-462. PubMed ID: 38282421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impacts of the 340B Program on health care quality for low-income patients.
    Smith K; Padmanabhan P; Chen A; Glied S; Desai S
    Health Serv Res; 2023 Oct; 58(5):1089-1097. PubMed ID: 37475113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
    Bond AM; Dean EB; Desai SM
    Health Aff (Millwood); 2023 May; 42(5):632-641. PubMed ID: 37126754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintaining qualification for 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Mar; 70(3):70-5. PubMed ID: 27183761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.